Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
Investing.com - Guggenheim raised its price target on Neurocrine Biosciences (NASDAQ:NBIX) to $175.00 from $165.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter earnings report. The $13.15 billion market cap company, which InvestingPro data shows has achieved a 21.73% revenue growth over the last twelve months, maintains a "GREAT" financial health score.
Neurocrine reported Ingrezza sales of approximately $624 million for the second quarter of 2025, slightly exceeding consensus estimates of $621 million. The company’s non-GAAP earnings per share reached $1.65, surpassing Street expectations of $1.52. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 3.13, while management has been actively buying back shares.
The biopharmaceutical firm narrowed its full-year 2025 Ingrezza sales guidance to $2.5-2.55 billion from the previous range of $2.5-2.6 billion, reflecting double-digit volume growth partially offset by lower net pricing due to expanded access initiatives.
Crenessity sales reached $53 million with 664 new patient enrollment start forms, significantly outperforming Street estimates of $24 million. The company also reported that all three pivotal studies in schizophrenia with its M4 agonist are progressing, with data expected in 2027-2028.
Neurocrine plans to host a Research and Development Day in San Diego on December 16, 2025, with upcoming catalysts including Phase II readout in Major Depressive Disorder with NBI-770 and Phase III readouts in Dyskinetic Cerebral Palsy, both expected in the fourth quarter of 2024.
In other recent news, Neurocrine Biosciences reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved earnings per share of $1.65, significantly higher than the projected $0.96, marking a 71.88% surprise. Revenue also exceeded forecasts, reaching $687.5 million compared to the anticipated $653.32 million, a 5.23% increase. Following these results, Mizuho (NYSE:MFG) raised its price target for Neurocrine to $145 from $140, maintaining a Neutral rating, citing solid performance of the Ingrezza medication and strong results for Crenessity. BMO Capital also increased its price target to $124 from $115, maintaining a Market Perform rating, based on higher projected revenues for Crenessity, which outperformed consensus expectations by 122%. These developments highlight recent positive momentum for Neurocrine, with analysts adjusting their outlooks based on the company’s financial performance and product success.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.